Clinical Protocols for Ketamine Therapy

Executive Summary for Healthcare Professionals

This clinical protocol guide provides evidence-based guidelines for healthcare professionals considering ketamine therapy implementation in their practice. The protocols below reflect current consensus from published literature, FDA guidance on off-label prescribing, and the practical experience of clinicians administering sublingual ketamine for treatment-resistant depression (TRD), generalized anxiety disorder (GAD), PTSD, and chronic pain syndromes.

These guidelines are not a substitute for clinical judgment. Every patient presents a unique risk-benefit calculus, and the prescribing physician bears ultimate responsibility for treatment decisions.

Patient Selection Criteria

The single decision with the largest influence on outcomes is whether to treat a given patient at all. Ketamine is not a general-purpose antidepressant; it is a specialized intervention for a specific profile of patient, and response rates deteriorate quickly when the treatment is offered outside that profile. The indications below reflect where the published evidence is strongest: treatment-resistant cases where conventional pharmacotherapy has genuinely failed, not cases where it simply hasn't been fully explored.

Primary Indications

Ketamine therapy is most strongly supported for:

• Treatment-resistant depression (TRD): failure of two or more adequate trials of first-line antidepressants (SSRI, SNRI, or bupropion) at therapeutic doses for at least 6 weeks each. McIntyre et al. (2021) in the American Journal of Psychiatry reported a 54% response rate in TRD patients receiving sublingual ketamine.
• Major depressive disorder with acute suicidal ideation: ketamine's rapid onset (hours, not weeks) provides a critical bridge while longer-acting treatments take effect. Wilkinson et al. (2018) demonstrated significant reduction in suicidal ideation within 24 hours.
• Generalized anxiety disorder refractory to first-line pharmacotherapy: emerging evidence supports ketamine's anxiolytic properties through NMDA receptor modulation and downstream AMPA activation.
• PTSD unresponsive to trauma-focused psychotherapy and pharmacotherapy: Feder et al. (2021) found significant PTSD symptom reduction in a randomized controlled trial of IV ketamine.
• Chronic pain syndromes with comorbid depression: particularly neuropathic pain, complex regional pain syndrome (CRPS), and fibromyalgia where central sensitization is a contributing mechanism.

Absolute Contraindications

The absolute exclusions below are not judgment calls. Each represents a scenario in which the evidence base, the pharmacology, or the clinical stakes make ketamine an unacceptable choice; the right clinical answer is to decline the referral and route the patient toward a safer alternative.

• Uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg at screening)
• Active psychotic disorder (schizophrenia, schizoaffective disorder, or current psychotic features)
• Known hypersensitivity to ketamine or arylcyclohexylamine compounds
• Pregnancy or active lactation
• Unstable intracranial pressure or active intracranial pathology
• Active substance use disorder involving ketamine, PCP, or other dissociative agents

Relative Contraindications Requiring Risk-Benefit Discussion

The relative contraindications are where clinical judgment matters most. Each is a situation where ketamine may still be appropriate (with dose adjustments, closer monitoring, or coordinated care with another specialist) but where the decision to proceed should be documented with explicit rationale and the patient's informed participation.

• Controlled hypertension (monitor closely; ketamine may transiently elevate BP by 15–25%)
• History of psychosis in remission (risk of relapse must be weighed against treatment benefit)
• Hepatic impairment (ketamine is hepatically metabolized; reduce dose and extend monitoring)
• Bipolar disorder (theoretical risk of mania induction, though published evidence is limited; proceed with mood stabilizer co-administration)
• Concurrent benzodiazepine use (may attenuate ketamine's antidepressant effect via GABAergic inhibition of NMDA-mediated neuroplasticity)

Pre-Treatment Assessment Protocol

The pre-treatment workup is where two goals converge: confirming that ketamine is the right clinical choice, and establishing the baseline against which treatment response will be measured. Skipping steps here (because the patient is suffering, because the referring physician was persuasive, because the schedule is tight) is one of the most reliable routes to a poor outcome. A thorough baseline now saves hours of uncertainty later.

Required Baseline Evaluations

1. Psychiatric assessment: PHQ-9, GAD-7, Columbia Suicide Severity Rating Scale (C-SSRS), and structured clinical interview confirming diagnosis and treatment resistance
2. Medical history and physical examination: focused cardiovascular and neurological exam
3. Vital signs: blood pressure, heart rate, respiratory rate (document baseline for comparison during sessions)
4. Laboratory studies: comprehensive metabolic panel (hepatic function), CBC, urinalysis, urine drug screen
5. Cardiac evaluation: ECG for patients over 50 or with cardiovascular risk factors
6. Pregnancy test: for all patients of childbearing potential
7. Medication reconciliation: particular attention to MAOIs (absolute contraindication for concurrent use), benzodiazepines (may reduce efficacy), and CYP3A4 inhibitors (may increase ketamine levels)

Informed Consent Requirements

Consent for ketamine is substantively different from consent for a standard prescription. The dissociative experience is, for most patients, unlike anything they've experienced pharmacologically, and the gap between a consent document and genuine understanding can be wide. The items below should be discussed in a conversation, in the patient's own words, before the form is signed.

The informed consent must specifically address:

• Off-label nature of sublingual ketamine for psychiatric indications
• Expected therapeutic effects and timeline (onset within hours to days; typical course of 10 or more sessions over 4–8 weeks)
• Common side effects: dissociation (incidence ~60%), nausea (~30%), elevated blood pressure (~20%), dizziness, blurred vision
• Rare but serious risks: laryngospasm, significant hypertensive crisis, emergence phenomena, urinary tract effects with chronic use
• Driving and heavy machinery restrictions (minimum 12 hours post-dose)
• That ketamine is a Schedule III controlled substance with abuse potential
• Treatment alternatives that have been tried and/or are available

Dosing Protocols

Dosing sublingual ketamine is a conservative art. The ranges below reflect the clinically useful middle: low enough to stay inside the therapeutic window for most patients, high enough to reliably produce the neuroplastic effect that the treatment depends on. Most failures of response in new programs trace either to under-dosing out of excess caution or to over-dosing in pursuit of a more dramatic experience. Neither produces the outcomes patients came for.

Sublingual (At-Home) Protocol

Sublingual ketamine (orally disintegrating tablets or troches) is the primary modality for at-home administration under telemedicine supervision.

Initial dosing:

• Start: 200–300 mg sublingual, held under the tongue for 10–15 minutes
• Patients should be instructed to avoid swallowing saliva during the hold period (bioavailability drops from ~30% sublingual to ~17% oral)
• First session should be conducted via synchronous telemedicine video with physician present for the full duration

Titration:

• Increase by 100 mg increments at subsequent sessions based on clinical response and tolerability
• Typical therapeutic range: 300–800 mg sublingual
• Maximum recommended dose: 1000 mg sublingual (higher doses increase dissociative side effects without proportional antidepressant benefit in most patients)

Session frequency:

• Induction phase (weeks 1–3): 2–3 sessions per week
• Consolidation phase (weeks 4–8): 1–2 sessions per week
• Maintenance phase: every 1–4 weeks based on symptom recurrence, titrated to the minimum effective frequency

Monitoring During Sessions

At-home monitoring works because sublingual ketamine at therapeutic doses has a narrow band of serious adverse events, and because the telemedicine relationship is genuine rather than nominal. The escalation triggers below exist precisely because the rare adverse event has to be caught quickly, and a patient who does not know to call the prescriber in a defined scenario is a patient whose safety depends on luck.

At-home sessions require telemedicine monitoring with defined escalation criteria:

• Blood pressure and heart rate: patient self-monitors at baseline, 30 minutes, and 60 minutes using a home cuff
• Escalation trigger: systolic >180 mmHg or diastolic >110 mmHg → instruct patient to remain supine, contact emergency services if not resolving within 15 minutes
• Dissociation assessment: monitor for distress during the dissociative window (typically 20–45 minutes post-dose)
• The treatment companion (required for at-home sessions) should be briefed on emergency procedures and have the prescribing physician's direct contact

Post-Session Documentation

Every session note functions as both a clinical record and, eventually, a legal one. Documentation that captures the specific data points below consistently, session after session, forms the outcome record that justifies treatment continuation, supports insurance appeals, and protects the practice in the rare event that a later review of care is requested.

Each session note must include:

• Pre-session PHQ-9 or equivalent validated depression measure
• Vital signs (baseline and peak)
• Dose administered, route, and hold time
• Onset and duration of dissociative effects (if any)
• Adverse events (nausea, hypertension, anxiety, emergence phenomena)
• Patient-reported subjective response
• Clinical assessment of treatment benefit vs. prior session
• Plan for next session (dose adjustment, frequency change, or taper)

Integration and Psychotherapy Coordination

Ketamine's neuroplastic window (the 24–72 hours following a session when BDNF upregulation and synaptogenesis are most active) represents a critical period for therapeutic integration. Practices offering ketamine therapy should:

• Coordinate with the patient's therapist (if separate from the prescriber) to schedule psychotherapy sessions during the neuroplastic window
• Provide structured integration prompts or journaling guides for patients to complete within 24 hours of a session
• Document the integration plan in the treatment record as part of the overall treatment plan

Quality Assurance and Outcome Tracking

A ketamine program that does not systematically measure outcomes is, in effect, practicing on anecdote. The measures below are not difficult to collect (a three-minute PHQ-9 before each session accumulates the data a practice needs to know whether its protocols are working) and the programs that run them consistently find themselves with clinical intuitions that are grounded in their own results rather than the published literature's.

Practices should establish a systematic outcome tracking protocol:

• Primary outcome measure: PHQ-9 score at baseline and before each session (clinically significant response defined as ≥50% reduction)
• Secondary measures: GAD-7, C-SSRS, patient-reported quality of life (WHO-5 or SF-36)
• Safety metrics: treatment-emergent adverse events, blood pressure elevations above threshold, unscheduled emergency contacts
• Program-level analytics: response rate, remission rate (PHQ-9 <5), treatment retention at 3 and 6 months, average sessions to response

These data support both clinical decision-making and regulatory compliance, and should be reviewed at minimum quarterly by the supervising physician.

Regulatory and Documentation Compliance

Ketamine is a Schedule III controlled substance. Practices must maintain:

• DEA registration appropriate for the practice type
• State-level prescribing authority for controlled substances via telemedicine (requirements vary by state; verify current regulations for each state in which patients are located)
• Prescription Drug Monitoring Program (PDMP) check before each new prescription and at minimum every 90 days for ongoing patients
• Secure prescription records per state and federal controlled substance documentation requirements
• HIPAA-compliant telemedicine platform for remote monitoring sessions

Frequently Asked Questions

What patient selection criteria define a good ketamine therapy candidate?

Strongest evidence for: treatment-resistant depression (failed ≥2 adequate antidepressant trials at therapeutic dose for 6-8 weeks), PHQ-9 ≥15 with functional impairment, PTSD refractory to first-line treatment (PCL-5 ≥33), severe anxiety where SSRIs and CBT have plateaued, and certain chronic pain syndromes (fibromyalgia, CRPS, neuropathic pain). Less appropriate: first-episode mild depression that hasn't been treatment-tested, situational depression that hasn't had adequate psychotherapy trial, primary substance use disorder. Patient profile fit is the single strongest outcome predictor.

What is the standard ketamine dosing protocol for treatment-resistant depression?

Standard sublingual ranges: 200-800 mg per session, titrated based on weight, response, and tolerability. Typical protocol: starting dose around 3-4 mg/kg, adjusted upward if response is partial and downward if dissociation is intolerable. Frequency: twice weekly for the first 2-3 weeks (loading phase), then tapered to weekly, then to maintenance intervals individualized by response. IV protocols use 0.5 mg/kg over 40 minutes; intramuscular protocols use ~0.5 mg/kg single injection. The exact regimen is patient-specific within these ranges.

What monitoring is required during ketamine therapy?

Pre-session: blood pressure check, confirmation of fasting status, sober support person present (for at-home), confirmation of patient psychiatric stability. During session: BP and pulse periodically, dissociation observation by support person or clinical staff, ability to call physician for any concerning response. Post-session: response assessment (mood scale, sleep, appetite), side-effect documentation (nausea, headache, urinary symptoms), and trended objective measures via standardized scales (PHQ-9, GAD-7, PCL-5) at regular intervals through the loading phase and maintenance.

What documentation should ketamine prescribers maintain?

Required elements: informed consent including dissociation, contraindications, abuse potential, off-label nature, and alternatives discussed; eligibility rationale including failed prior trials with specific medications/doses/durations; pre-session vital signs and confirmation of safety preconditions; session-specific dose, route, and any unusual events; post-session response and side effects; trended outcome measures (PHQ-9, GAD-7, PCL-5) at appropriate intervals; correspondence with referring providers as appropriate. The documentation standard is the same as for any controlled substance prescription, with extra attention to off-label-use rationale.

Coordinating ketamine therapy for a patient in Florida or New Jersey?

Tovani Health is a physician-led at-home ketamine therapy practice operating under the protocols outlined above. We coordinate care with referring providers throughout treatment and welcome protocol-related questions about specific patients you've referred or are considering referring.

Refer a patient via /eligibility →

Want to discuss a case directly? Call 561-468-6981.

Benjamin Soffer, DO — Tovani Health

---

Related professional reading: clinical supervision protocols, medical supervision standards for at-home programs, emergency management protocols, psychiatric consultation protocols, evidence-based outcomes review.

This protocol guide is developed by Tovani Health for use by licensed healthcare professionals. It does not constitute medical advice for patients. Clinicians should exercise independent clinical judgment in all treatment decisions.